205 related articles for article (PubMed ID: 31264356)
21. Evolving of therapeutic strategies for CNS-PNET.
Massimino M; Gandola L; Biassoni V; Spreafico F; Schiavello E; Poggi G; Pecori E; Vajna De Pava M; Modena P; Antonelli M; Giangaspero F
Pediatr Blood Cancer; 2013 Dec; 60(12):2031-5. PubMed ID: 23852767
[TBL] [Abstract][Full Text] [Related]
22. Abundance of apoptotic neoplastic cells in diagnostic biopsy samples is not a prognostic factor in childhood primitive neuroectodermal tumors of the central nervous system.
Grotzer MA; Janss AJ; Fung KM; Sutton LN; Zhao H; Trojanowski JQ; Rorke LB; Phillips PC
J Pediatr Hematol Oncol; 2001 Jan; 23(1):25-9. PubMed ID: 11196266
[TBL] [Abstract][Full Text] [Related]
23. Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma.
Ho DM; Hsu CY; Wong TT; Ting LT; Chiang H
Acta Neuropathol; 2000 May; 99(5):482-8. PubMed ID: 10805090
[TBL] [Abstract][Full Text] [Related]
24. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
[TBL] [Abstract][Full Text] [Related]
25. Receiver operating characteristic curve analysis of SEER medulloblastoma and primitive neuroectodermal tumor (PNET) outcome data: identification and optimization of predictive models.
Cheung MR
Asian Pac J Cancer Prev; 2014; 15(16):6781-5. PubMed ID: 25169525
[TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
[TBL] [Abstract][Full Text] [Related]
27. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Nordfors K; Haapasalo J; Korja M; Niemelä A; Laine J; Parkkila AK; Pastorekova S; Pastorek J; Waheed A; Sly WS; Parkkila S; Haapasalo H
BMC Cancer; 2010 Apr; 10():148. PubMed ID: 20398423
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors.
Bakish J; Hargrave D; Tariq N; Laperriere N; Rutka JT; Bouffet E
Cancer; 2003 Sep; 98(5):1014-20. PubMed ID: 12942570
[TBL] [Abstract][Full Text] [Related]
29. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
Allen JC; Donahue B; DaRosso R; Nirenberg A
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
[TBL] [Abstract][Full Text] [Related]
30. Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors.
Dufour C; Kieffer V; Varlet P; Raquin MA; Dhermain F; Puget S; Valteau-Couanet D; Grill J
Pediatr Blood Cancer; 2014 Aug; 61(8):1398-402. PubMed ID: 24664937
[TBL] [Abstract][Full Text] [Related]
31. RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
Inda MM; Castresana JS
Neuropathology; 2007 Aug; 27(4):341-6. PubMed ID: 17899687
[TBL] [Abstract][Full Text] [Related]
32. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors.
Grotzer MA; Janss AJ; Phillips PC; Trojanowski JQ
Klin Padiatr; 2000; 212(4):196-9. PubMed ID: 10994550
[TBL] [Abstract][Full Text] [Related]
33. [Survival and prognostic factors analysis of primitive neuroectodermal tumor].
Shen J; Yuan Y; Hu K; Lian X; Hou XR; Sun S; Yan JF; Liu ZK; Zhang FQ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):614-618. PubMed ID: 30139033
[No Abstract] [Full Text] [Related]
34. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
[TBL] [Abstract][Full Text] [Related]
35. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.
McNeil DE; Coté TR; Clegg L; Rorke LB
Med Pediatr Oncol; 2002 Sep; 39(3):190-4. PubMed ID: 12210449
[TBL] [Abstract][Full Text] [Related]
36. M1 Medulloblastoma: high risk at any age.
Sanders RP; Onar A; Boyett JM; Broniscer A; Morris EB; Qaddoumi I; Armstrong GT; Boop FA; Sanford RA; Kun LE; Merchant TE; Gajjar A
J Neurooncol; 2008 Dec; 90(3):351-5. PubMed ID: 18704266
[TBL] [Abstract][Full Text] [Related]
37. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
38. Prognostic importance of cellular differentiation in medulloblastoma of childhood.
Packer RJ; Sutton LN; Rorke LB; Littman PA; Sposto R; Rosenstock JG; Bruce DA; Schut L
J Neurosurg; 1984 Aug; 61(2):296-301. PubMed ID: 6737054
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemotherapy and overall survival in adult medulloblastoma.
Kann BH; Lester-Coll NH; Park HS; Yeboa DN; Kelly JR; Baehring JM; Becker KP; Yu JB; Bindra RS; Roberts KB
Neuro Oncol; 2017 Feb; 19(2):259-269. PubMed ID: 27540083
[TBL] [Abstract][Full Text] [Related]
40. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.
Hong TS; Mehta MP; Boyett JM; Donahue B; Rorke LB; Zeltzer PM
Pediatr Blood Cancer; 2005 Oct; 45(5):676-82. PubMed ID: 16007595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
